MOCHIDA PHARMACEUTICAL CO LTD has a total of 27 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 1983. It filed its patents most often in Australia, Taiwan and Serbia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are MOCHIDA PHARM CO LTD, SPIROGEN SARL and WYETH HOLDINGS CO.
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Measurement | |
#5 | Medical technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Object sterilising | |
#7 | Microorganisms | |
#8 | Fermentation | |
#9 | Microorganisms | |
#10 | Organic chemistry methods |
# | Name | Total Patents |
---|---|---|
#1 | Shirakawa Kamon | 6 |
#2 | Makabe Muneyoshi | 5 |
#3 | Ohkouchi Munetaka | 5 |
#4 | Okano Akihiro | 5 |
#5 | Igarashi Tatsuya | 3 |
#6 | Kasahara Yasuhiko | 3 |
#7 | Minami Akio | 3 |
#8 | Kawamura Daisuke | 3 |
#9 | Ohzawa Nobuo | 3 |
#10 | Iwasaki Norimasa | 3 |
Publication | Filing date | Title |
---|---|---|
TW201836637A | Liquid pharmaceutical agent comprising antibody characterized by realizing the stability of dimer formation inhibition and deamidation inhibition during long-term storage and being suitable for a wide range of antibody concentration | |
AU2016319444A1 | Freeze-dried alginic acid preparation | |
TW201626988A | Self-emulsifying composition of ω3 fatty acid | |
TW201938143A | Self-emulsifying formulation and self-emulsifying composition of [omega]3 fatty acid exhibiting excellent self-emulsifying property, composition dispersing ability, emulsification stability and absorbability | |
AU2013204006A1 | Composition for treatment of cartilage disease | |
AU2012256683A1 | Diagnosis of respiratory tract infectious diseases using urine specimens | |
AU2010336225A1 | Novel 3-hydroxy-5-arylisothiazole derivative | |
AU2010312365A1 | Novel 3-hydroxy-5-arylisoxazole derivative | |
AU7333296A | Meltrins |